MBNL1 and myotonic dystrophy type 1: Peptoid-based therapeutics have shown some promising results in mitigating RNA toxicity in DM1 models by reducing the interaction between CUG repeats and MBNL1 and decreasing foci formation (Pushechnikov et al., 2009; García-López et al., 2011; Rzuczek et al., 2013).